Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

NDA FilingXPOVIOruxolitinibPositive

AI Analysis

Summary

Karyopharm Therapeutics submitted a supplemental NDA to the FDA for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis patients, requesting Accelerated Approval and Priority Review pathways.

Outcome Details

Supplemental New Drug Application submitted under Accelerated Approval Pathway with Priority Review requested

Importance:7/10

Sentiment:

0.60

FDA submissionAccelerated ApprovalPriority Reviewcombination therapymyelofibrosis

Related Companies

$KPTI

Read the original article

Published by PR Newswire Pharma on August 31, 2026 11:30 AM

Read Original